The review concluded that pneumococcal conjugate vaccine produced a significant effect regarding prevention of invasive pneumococcal disease. The effects on prevention of otitis media and pneumonia were less striking. The review had some methodological problems (notably potential for heterogeneity and uncertain quality of individual trials) which mean that caution is warranted when interpreting the authors' conclusions.
Authors' objectives
To determine the protective clinical efficacy of pneumococcal conjugate vaccine (PCV) in reducing the incidence of invasive pneumococcal disease, pneumonia and acute otitis media in healthy infants younger than 24 months.
Searching
MEDLINE and EMBASE were searched from January 2000 to June 2008 for articles published in English. Search terms were reported. Reference lists of retrieved trials and review articles were searched.
Study selection
Randomised controlled trials (RCTs) that compared placebo or control vaccines with the protective efficacy of a series of PCV immunisations (three to four doses of any valency) in healthy infants younger than 24 months were eligible for inclusion. PCV had to be given before 12 months of age. Trials needed to provide intention-to-treat or per protocol data on the incidence of invasive pneumococcal disease, acute otitis media or pneumonia. Definitions were reported in the review.
The included trials studied PCV given three or four times between the ages of two months and 15 months. Vaccine valency was PCV-7 in most trials; PCV-9 and PCV-11 were also studied. Age at enrollment ranged from two to 24 months.
Two reviewers independently performed study selection. Disagreements were resolved by consensus.
Assessment of study quality
Two reviewers independently assessed trial quality according to Jadad and Chalmers' scales. The number of trials that met each quality item was calculated. Discrepancies were resolved by consensus.
Data extraction
Two reviewers independently extracted data on incidence of invasive pneumococcal disease, acute otitis media and pneumonia. Data were used to calculate relative risks (RR) and 95% confidence intervals (CI). Discrepancies between reviewers were resolved by consensus.
Methods of synthesis
A DerSimonian and Laird random-effects meta-analysis was used to calculate pooled relative risks and 95% CIs. Risk reduction was calculated (1-RR). Sensitivity analysis was undertaken for PCV-7 and use of fixed-effect modelling. Publication bias was estimated by funnel plot assessment.
